NS Investment: Funding, Team & Investors | Startup Intros

Loading organizations...

NS Investment: Funding, Team & Investors | Startup Intros

Financial History

Total Raised

N/A

Valuation

N/A

Investments Made

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
May 1, 2022	Aspen Neuroscience	$150.0M Series B	Google Ventures, LYFE Capital, Doug Fisher	Chloe Sladden, CRV, F-Prime Capital Partners, InterWest, Maven Ventures, NextView Ventures, OrbiMed, Otherwise Fund, Tiger Global Management, Tribe Capital, Dafina Toncheva, Y Combinator, Sam Altman, EDBI, Alexandria Venture Investments, ARCH Venture Partners, Frazier Life Sciences, LifeForce Capital, Medical Excellence Capital, Mirae Asset Capital, Newton Investment Management North America, Section 32
Feb 1, 2022	Dewpoint Therapeutics	$150.0M Series C	SoftBank	Andreessen Horowitz, ARCH Venture Partners, Blue Horizon, Concrete Rose Capital, John Hamer, Next Play Ventures, Polaris Partners, Predictive VC, Serena Ventures, SignalFire, Sinai Ventures, SoftBank Investment Advisers, Zeal Capital Partners, Gregory Waldorf, Ollen Douglass, 3E Bioventures Capital, EcoR1 Capital, General Catalyst, Juergen Eckhardt, Maverick Ventures, Mirae Asset Capital, Mubadala Capital, Polaris Partners, Samsara BioCapital
Oct 1, 2021	ReCode Therapeutics	$80.0M Series B	Oleg Nodelman	Bioluminescence Ventures, InterWest, MPM Capital, OrbiMed, Pfizer Venture Investments, Polaris Partners, Vida Ventures, Sam Altman, Colt Ventures, Hunt Technology Ventures, Osage University Partners, Sanofi Ventures, Superstring Capital, Tekla Capital Management
Aug 1, 2021	Immunitas Therapeutics	$58.0M Series B	Agent Capital	Alta Partners, Cofounders Capital, Domain Associates, Leaps by Bayer, Longwood Fund, Novartis Venture Fund, Providence Ventures, RA Capital, Section 32, Netalie Nadivi, 120 Capital, Alexandria Venture Investments, Evotec, Brian Halak, Mirae Asset, M Ventures, Novartis, Ono Venture Investment, Solasta Ventures, The Leukemia & Lymphoma Society, The Mark Foundation for Cancer Research
Apr 1, 2020	Accent Therapeutics	$63.0M Series B	Oleg Nodelman	Atlas Venture, F-Prime Capital Partners, Nextech Invest, The Column Group, AbbVie Ventures, Droia Ventures, Google Ventures, The Mark Foundation for Cancer Research
Mar 1, 2020	Silverback Therapeutics	$79.0M Series B	U.S. Venture Partners	Andreessen Horowitz, Canaan Partners, Deerfield Management, Nextech Invest, Alexandria Venture Investments, Bristol Myers Squibb, Colt Ventures, Hunt Investment Group, Thilo Schroeder, OrbiMed, Pontifax
Mar 1, 2019	Surrozen	$50.0M Series B	—	Canaan Partners, The Column Group, Hartford HealthCare Endowment, Horizons Ventures
Nov 1, 2018	Harpoon Therapeutics	$70.0M Series C	Arix Bioscience	Canaan Partners, Cormorant Asset Management, Lilly Asia Ventures, MPM Capital, New Leaf Venture Partners, Oncology Impact Fund, OrbiMed, Ridgeback Capital Investments, Taiho Ventures
Nov 1, 2018	NextCure	$93.0M Series B	Michael Yi, Stella Xu	5AM Ventures, Access Biotechnology, Canaan Partners, Connecticut Innovations, Endeavor Venture Funds, Nextech Invest, OrbiMed, RA Capital, Alexandria Venture Investments, ArrowMark Partners, Bay City Capital, Canaan Partners, Lilly Asia Ventures, Pfizer, Ping An Ventures, Sofinnova Ventures, Surveyor Capital, Taiho Ventures
Apr 9, 2018	Constellation Pharmaceuticals	$100.0M Other Equity	—	Casdin Capital, Cormorant Asset Management, Deerfield Management, Fidelity Management & Research Company, Hillhouse Capital, OrbiMed, Sirona Capital, SR One, The Column Group, Third Rock Ventures, Topspin Partners, University of California, Venrock
Feb 21, 2018	ORIC Pharmaceuticals	$50.0M Series C	—	EcoR1 Capital, Fidelity Management & Research Company, Foresite Capital, Kravis Investment Partners, Memorial Sloan Kettering Cancer Center, OrbiMed, Taiho Ventures, The Column Group, Topspin Fund, Trinitas Capital
Mar 1, 2017	Antiva Biosciences	$22.0M Series C	Vinzenz Ploerer	Canaan Partners, Johnson & Johnson Innovation, Osage University Partners, Alexandria Venture Investments, Canaan Partners, Sofinnova Ventures